Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, shares his thoughts on updates in the field of lymphoma as presented at ASH 2020. Dr Mehta highlights promising early data from studies investigating bispecific antibodies such as mosunetuzumab both with and without chemotherapy, as well as advances in chimeric antigen receptor (CAR) T-cell therapy and results from the ZUMA-5 (NCT03105336) and ELARA trials. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.